Competitive antagonists of bradykinin

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Peptide Science

Background:

• Bradykinin (BK) is a peptide involved in various physiological processes, including blood pressure regulation and smooth muscle contraction.
• Development of specific antagonists for BK is crucial for understanding its role and for potential therapeutic applications.
• Previous efforts focused on identifying sequence-related inhibitors of BK activity.

Purpose of the Study:

• To develop the first sequence-related competitive inhibitors of bradykinin (BK).
• To investigate the structure-activity relationships of modified BK analogs as antagonists.
• To evaluate the efficacy and specificity of these inhibitors in vitro and in vivo.

Main Methods:

• Peptide synthesis involving sequential amino acid substitutions in the bradykinin sequence.
• In vitro assays using isolated rat uterus and guinea pig ileum to assess myotropic activity and BK antagonism.
• In vivo assays measuring rat blood pressure to evaluate depressor potency and antagonist activity.

Main Results:

• Modification of proline at position 7 to D-phenylalanine ([D-Phe7]-BK) yielded a moderate BK antagonist with some residual agonist activity.
• Further modification replacing phenylalanine residues at positions 5 and 8 with beta-(2-thienyl)-alanine resulted in potent and specific BK antagonists.
• These potent antagonists demonstrated competitive and reversible inhibition of BK, kallidin, and Met-Lys-BK on smooth muscle, without affecting angiotensin or substance P.

Conclusions:

• The developed peptide analogs represent the first sequence-related competitive inhibitors of bradykinin.
• Specific amino acid substitutions, particularly at positions 5, 7, and 8, are critical for converting BK agonists into potent and selective antagonists.
• These novel BK antagonists offer valuable tools for studying kinin pathways and hold potential for therapeutic development.